Breakthrough therapies are changing how we treat serious and complex conditions, including cancer, autoimmune diseases, and rare genetic disorders. These advances offer real hope for patients, but their rapidly rising costs are r significantly impacting affordability of employer sponsored healthcare coverage.
Specialty drugs are now one of the fastest growing drivers of pharmacy spending, accounting for more than half of total prescription drug costs while serving a relatively small number of patients.
Some therapies enter the market with multimillion dollar price tags, fundamentally altering the cost equation for employer health plans. Recent gene therapies illustrate the scale of this shift. Lenmeldy, a treatment for a rare and fatal childhood neurological disease, is priced at $4.25 million per patient. Hemgenix, a gene therapy for hemophilia B, costs $3.5 million per treatment. Even when clinically appropriate and life changing, a single therapy can materially affect premiums and out-of-pocket costs for workers and families.
Newer drug classes such as GLP-1 medications highlight both opportunity and risk. These
treatments can improve chronic disease outcomes, but they often cost $10,000 to $15,000 per patient per year and are typically used long term. Without strategies to ensure appropriate use and value, broader adoption could significantly increase total pharmacy spending.
Where specialty drugs are delivered also matters. Medications administered in hospital-owned outpatient departments often come with higher reimbursement rates and facility fees than those delivered in independent clinics or home-based settings, even when the clinical care is the same.
As hospitals expand ownership of infusion centers and specialty practices, the higher costs that accompany these site-of-care shifts are becoming increasingly visible to employers and members.
The challenge ahead is not whether pharmaceutical innovation will continue, but whether the system can support access to these new treatments without undermining the affordability of healthcare overall. Employers and families are increasingly focused on ensuring drug spending reflects clinical value; lower cost alternatives are used when available, and care is delivered in the most appropriate settings. Innovation and affordability must move forward together if coverage is to remain sustainable.
How Premera is responding:
Premera is taking a value-based approach to pharmacy affordability, focused on preserving access while protecting coverage stability. Our approach includes:
- Expanding the use of biosimilars, which deliver the same clinical effectiveness as brand name biologics at significantly lower cost
- After biosimilars entered the market, Humira dropped out of Premera’s top five drugs by total spend, a position it had held for more than five years
- Promoting clinically appropriate site-of-care strategies for specialty medications, helping shift treatment away from unnecessarily high-cost hospital settings when safe and effective alternatives exist
- Advocating for policies that strengthen competition, including reducing practices that delay access to lower cost generics and biosimilars and drive up costs across the system
